Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
AJNR Am J Neuroradiol. 2012 Jun;33(6):1187-90. doi: 10.3174/ajnr.A2932. Epub 2012 Mar 1.
Cerebral venous thrombosis is a rare entity that can be difficult to manage. Most patients with cerebral sinus thrombosis recover after treatment with heparin, but a subgroup of severe cerebral venous sinus thrombosis has a poor prognosis. Those patients may benefit from intrasinus thrombolysis. The purpose of this research was to carry out a retrospective analysis of patients with severe cerebral venous sinus thrombosis, and to study the safety and efficacy of intrasinus thrombolysis in patients with cerebral venous sinus thrombosis unresponsive to conventional heparin therapy.
Thirty-seven patients with cerebral venous sinus thrombosis who received intrasinus thrombolysis during a 3-year period (January 2007 to December 2009) were included in this study. Urokinase was infused into the sinus via a microcatheter. Data regarding demographic, clinical, and radiologic features were collected. Follow-up data were obtained at 6 months. MRV was repeated to assess the recanalization of the venous sinus.
Twenty-seven patients (73%) had good outcome and 7 patients (19%) who were independent for activities of daily life had only mild deficits. One patient survived with severe neurologic deficits and 2 patients died. Complete recanalization of the superior sagittal sinus was seen in 35 patients (97%). At a follow-up of 6 months, 34 patients (92%) were either asymptomatic or had only minor subjective symptoms.
Intrasinus thrombolysis is safe and effective in patients with severe cerebral venous sinus thrombosis. However, the subgroup of patients that is likely to benefit the most from this procedure is not clear from our data. Large randomized controlled trials are required to further clarify this issue.
脑静脉血栓形成是一种罕见的疾病,治疗较为困难。大多数脑窦血栓形成患者在接受肝素治疗后可恢复,但部分严重脑静脉窦血栓形成患者预后较差。这些患者可能受益于窦内溶栓。本研究旨在对严重脑静脉窦血栓形成患者进行回顾性分析,研究静脉窦内溶栓治疗对常规肝素治疗无效的脑静脉窦血栓形成患者的安全性和有效性。
本研究纳入了 37 例在 3 年期间(2007 年 1 月至 2009 年 12 月)接受静脉窦内溶栓治疗的脑静脉窦血栓形成患者。通过微导管向窦内注入尿激酶。收集人口统计学、临床和影像学特征的数据。在 6 个月时获得随访数据。重复磁共振静脉造影(MRV)以评估静脉窦再通情况。
27 例(73%)患者预后良好,7 例(19%)日常生活活动能力独立的患者仅有轻度残疾。1 例患者存活但存在严重神经功能缺损,2 例患者死亡。35 例患者(97%)上矢状窦完全再通。在 6 个月的随访中,34 例患者(92%)无症状或仅有轻微的主观症状。
静脉窦内溶栓治疗对严重脑静脉窦血栓形成患者是安全有效的。然而,我们的数据并不能明确哪些患者最有可能从该治疗中受益。需要开展大规模随机对照试验进一步阐明这个问题。